Monitoring Acetylsalicylic Acid Effects with the Platelet Function Analyzer PFA-100

 

 Buy Article Permissions and Reprints

ABSTRACT

The efficacy of acetylsalicylic acid (ASA) to prevent thrombotic or embolic events in patients with atherosclerosis was demonstrated in many large trials. Despite this fact, a subpopulation of patients experiences acute myocardial infarction or cerebrovascular ischemia indicating a nonresponsiveness to ASA. These patients would be candidates for an alternative or additional antiplatelet therapy, if they could be reliably identified. The aim of the monitoring of ASA therapy should be the identification of nonresponders to prevent a long-term intake of the drug without adequate benefit, to justify a dose escalation, or to initiate an alternative antiplatelet drug therapy.

Considerable progress has been made in the measurement of platelet function. One of the novel devices employed is the platelet function analyzer PFA-100, which was already tested in several studies involving patients with atherothrombosis to detect nonresponsiveness to ASA. Many of these investigations indicate that the PFA-100 could be used for routine identification of nonresponders to ASA and-probably also-for tailoring antiplatelet therapy. The aim of this article is to summarize the data obtained from the studies focusing on the monitoring of ASA therapy by the PFA-100.

REFERENCES

• 1 Antiplatelet Trialists’ Collaboration . Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.  BMJ. 1994;  308 81-106
  PubMedGoogle Scholar
• 2 Antiplatelet Trialists’ Collaboration . Collaborative overview of randomised trials of antiplatelet therapy-II: maintenance of vascular graft or arterial patency by antiplatelet therapy.  BMJ. 1994;  308 159-168
  CrossrefPubMedGoogle Scholar
• 3 Antiplatelet Trialists’ Collaboration . Collaborative overview of randomised trials of antiplatelet therapy-III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients.  BMJ. 1994;  308 235-246
  Google Scholar
• 4 Helgason C M, Bolin K M, Hoff J A et al.. Development of aspirin resistance in persons with previous ischemic stroke.  Stroke. 1994;  25 2331-2336
  CrossrefPubMedGoogle Scholar
• 5 Vejar M, Fragasso G, Hackett D et al.. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina.  Thromb Haemost. 1990;  63 163-168
  PubMedGoogle Scholar
• 6 Mammen E F, Comp P C, Gosselin R et al.. PFA-100 system: a new method for assessment of platelet dysfunction.  Semin Thromb Hemost. 1998;  24 195-202
  Article in Thieme ConnectPubMedGoogle Scholar
• 7 Kundu S K, Heilmann E J, Sio R, Garcia C, Davidson R M, Ostgaard R A. Description of an in vitro platelet function analyzer-PFA-100.  Semin Thromb Hemost. 1995;  21(Suppl 2) 106-112
  PubMedGoogle Scholar
• 8 Grotemeyer K H. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients.  Thromb Res. 1991;  63 587-593
  CrossrefPubMedGoogle Scholar
• 9 Hurlen M, Seljeflot I, Arnesen H. The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction.  Scand Cardiovasc J. 1998;  32 233-237
  CrossrefPubMedGoogle Scholar
• 10 Moeller A, Weippert-Kretschmer M, Prinz H, Kretschmer V. Influence of ABO blood groups on primary hemostasis.  Transfusion. 2001;  41 56-60
  CrossrefPubMedGoogle Scholar
• 11 Lippi G, Franchini M, Brocco G, Manzato F. Influence of the ABO blood type on the platelet function analyzer PFA-100.  Thromb Haemost. 2001;  85 369-370
  PubMedGoogle Scholar
• 12 Dalby M C, Davidson S J, Burman J F, Davies S W. Diurnal variation in platelet aggregation with the PFA-100 platelet function analyser.  Platelets. 2000;  11 320-324
  CrossrefPubMedGoogle Scholar
• 13 Feuring M, Haseroth K, Janson C P, Falkenstein E, Schmidt B M, Wehling M. Inhibition of platelet aggregation after intake of acetylsalicylic acid detected by a platelet function analyzer (PFA-100).  Int J Clin Pharmacol Ther. 1999;  37 584-588
  PubMedGoogle Scholar
• 14 Gum P A, Kottke-Marchant K, Poggio E D et al.. Profile and prevalence of aspirin resistance in patients with cardiovascular disease.  Am J Cardiol. 2001;  88 230-235
  CrossrefPubMedGoogle Scholar
• 15 Peters A J, Borries M, Gradaus F, Jax T W, Schoebel F C, Strauer B E. In vitro bleeding test with PFA-100-aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease.  J Thromb Thrombolysis. 2001;  12 263-272
  CrossrefPubMedGoogle Scholar
• 16 Christiaens L, Macchi L, Herpin D et al.. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease.  Thromb Res. 2002;  108 115-119
  CrossrefPubMedGoogle Scholar
• 17 Macchi L, Christiaens L, Brabant S et al.. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate.  Thromb Res. 2002;  107 45-49
  CrossrefPubMedGoogle Scholar
• 18 Gianrossi R, Detrano R, Mulvihill D et al.. Exercise-induced ST depression in the diagnosis of coronary artery disease. A meta-analysis.  Circulation. 1989;  80 87-98
  CrossrefPubMedGoogle Scholar
• 19 Ashley E A, Myers J, Froelicher V. Exercise testing in clinical medicine.  Lancet. 2000;  356 1592-1597
  CrossrefPubMedGoogle Scholar
• 20 Lanza G A, Sestito A, Iacovella S et al.. Relation between platelet response to exercise and coronary angiographic findings in patients with effort angina.  Circulation. 2003;  107 1378-1382
  CrossrefPubMedGoogle Scholar
• 21 Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease.  Thromb Res. 2002;  108 37-42
  CrossrefPubMedGoogle Scholar
• 22 Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks.  J Neurol. 2003;  250 63-66
  CrossrefPubMedGoogle Scholar
• 23 Roller R E, Dorr A, Ulrich S, Pilger E. Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100.  Blood Coagul Fibrinolysis. 2002;  13 277-281
  CrossrefPubMedGoogle Scholar
• 24 Mueller T, Haltmayer M, Poelz W, Haidinger D. Monitoring aspirin 100 mg and clopidogrel 75 mg therapy with the PFA-100 device in patients with peripheral arterial disease.  Vasc Endovascular Surg. 2003;  37 117-123
  CrossrefPubMedGoogle Scholar
• 25 Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction.  J Lab Clin Med. 2001;  138 152-163
  CrossrefPubMedGoogle Scholar
• 26 Grau A J, Reiners S, Lichy C, Buggle F, Ruf A. Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study.  Stroke. 2003;  34 849-854
  CrossrefPubMedGoogle Scholar
• 27 Malinin A I, Atar D, Callahan K P, McKenzie M E, Serebruany V L. Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease.  Eur J Pharmacol. 2003;  462 139-143
  CrossrefPubMedGoogle Scholar
• 28 Grotemeyer K H, Scharafinski H W, Husstedt I W. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients.  Thromb Res. 1993;  71 397-403
  CrossrefPubMedGoogle Scholar
• 29 Eikelboom J W, Hirsh J, Weitz J I, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events.  Circulation. 2002;  105 1650-1655
  CrossrefPubMedGoogle Scholar
• 30 Ziegler S, Alt E, Brunner M, Speiser W, Minar E. Influence of systemic inflammation on the interpretation of response to antiplatelet therapy, monitored by PFA-100.  Semin Thromb Hemost. 2005;  31 416-419
  Article in Thieme ConnectPubMedGoogle Scholar

 Prof. Dr.
M. Wehling

Institute of Clinical Pharmacology, Faculty of Clinical Medicine Mannheim, University of Heidelberg

68135 Mannheim, Germany

Email: martin.wehling@kpha.ma.uni-heidelberg.de